Cullinan Therapeutics Management
Management criteria checks 1/4
Cullinan Therapeutics' CEO is Nadim Ahmed, appointed in Oct 2021, has a tenure of 4.25 years. total yearly compensation is $7.68M, comprised of 8.8% salary and 91.2% bonuses, including company stock and options. directly owns 0.11% of the company’s shares, worth $661.35K. The average tenure of the management team and the board of directors is 3.9 years and 2.6 years respectively.
Key information
Nadim Ahmed
Chief executive officer
US$7.7m
Total compensation
| CEO salary percentage | 8.78% |
| CEO tenure | 4.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 3.9yrs |
| Board average tenure | 2.6yrs |
Recent management updates
Recent updates
Cullinan Therapeutics: Worthy Of A Small Position
Oct 17Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation
Oct 10
Here's Why We're Watching Cullinan Therapeutics' (NASDAQ:CGEM) Cash Burn Situation
Jun 21Cullinan Therapeutics: Attractive Pipeline Progress, But We Will Wait For Complete Phase 2b Data
Apr 08Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans
Feb 27Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Jan 08Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans
Nov 20Cullinan Therapeutics: Fundraising Capability, Emergence In Autoimmune Disease
Aug 30Checking Into Cullinan Therapeutics
Jun 09Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth
Apr 23Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Sep 22Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
Sep 14Cullinan Oncology grants stock options for 125.7K shares
Sep 02Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth
Jun 24Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation
Mar 05CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$217m |
| Jun 30 2025 | n/a | n/a | -US$207m |
| Mar 31 2025 | n/a | n/a | -US$179m |
| Dec 31 2024 | US$8m | US$675k | -US$167m |
| Sep 30 2024 | n/a | n/a | -US$144m |
| Jun 30 2024 | n/a | n/a | -US$142m |
| Mar 31 2024 | n/a | n/a | -US$132m |
| Dec 31 2023 | US$4m | US$649k | -US$153m |
| Sep 30 2023 | n/a | n/a | -US$156m |
| Jun 30 2023 | n/a | n/a | -US$142m |
| Mar 31 2023 | n/a | n/a | US$65m |
| Dec 31 2022 | US$4m | US$618k | US$111m |
| Sep 30 2022 | n/a | n/a | US$105m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$39m | US$125k | -US$66m |
Compensation vs Market: Nadim's total compensation ($USD7.68M) is above average for companies of similar size in the US market ($USD2.29M).
Compensation vs Earnings: Nadim's compensation has increased whilst the company is unprofitable.
CEO
Nadim Ahmed (57 yo)
Mr. Nadim Ahmed is Director of Disc Medicine, Inc. from July 2025. Mr. Ahmed has been a President, Chief Executive Officer and Director of Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$7.68m | 0.11% $ 661.3k | |
| Chief Financial Officer | 1.8yrs | US$4.14m | 0.10% $ 619.7k | |
| Chief Medical Officer | 3.9yrs | US$3.39m | 0.068% $ 401.1k | |
| Co-Founder | no data | US$1.96m | no data | |
| Chief Scientific Officer | 2.6yrs | no data | 0.055% $ 326.8k | |
| Head of Investor Relations | no data | no data | no data | |
| Chief Legal Officer | 3.4yrs | no data | 0.058% $ 341.9k | |
| Chief Human Resources Officer | 4yrs | no data | no data | |
| Chief Business Officer | 8.9yrs | no data | 0.26% $ 1.5m | |
| Senior Vice President of Corporate Affairs | 2yrs | no data | no data | |
| Chief Technical Operations Officer | 4yrs | no data | no data |
Experienced Management: CGEM's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 4.3yrs | US$7.68m | 0.11% $ 661.3k | |
| Co-Founder | 2.6yrs | US$1.96m | no data | |
| Independent Director | 5.3yrs | US$229.86k | 0% $ 0 | |
| Independent Chairman of the Board | 8.4yrs | US$258.41k | 0.076% $ 449.6k | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Director | 1.4yrs | US$292.55k | no data | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2yrs | no data | no data | |
| Independent Director | 1.7yrs | US$304.48k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.6yrs | no data | no data |
Experienced Board: CGEM's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/06 12:55 |
| End of Day Share Price | 2026/01/06 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cullinan Therapeutics, Inc. is covered by 16 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julian Harrison | BTIG |
| Thomas Shrader | BTIG |
| Kaveri Pohlman | BTIG |